Market Cap | 125.63M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -333.56M | Forward P/E | - | EPS next Y | 44.40% | 50D Avg Chg | -4.00% |
Sales | 544.09M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -78.00% |
Dividend | N/A | Price/Book | 0.17 | EPS next 5Y | - | 52W High Chg | -93.00% |
Recommedations | 2.00 | Quick Ratio | 0.71 | Shares Outstanding | 188.33M | 52W Low Chg | 21.00% |
Insider Own | 81.43% | ROA | -10.14% | Shares Float | 17.10M | Beta | 0.55 |
Inst Own | 4.98% | ROE | -77.80% | Shares Shorted/Prior | 95.94K/116.76K | Price | 1.35 |
Gross Margin | 80.24% | Profit Margin | -66.77% | Avg. Volume | 711,904 | Target Price | 4.18 |
Oper. Margin | -49.50% | Earnings Date | - | Volume | 62,646 | Change | -3.57% |
YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.
Noble Capital Markets | Outperform | Nov 13, 23 |